Zelluna ASA Reports First Quarter 2025 Financial Results
Zelluna ASA, a pioneer in developing innovative allogeneic T Cell Receptor based Natural Killer (TCR-NK) cells for cancer treatment, has announced its financial results for the first quarter of the year. The company aims to provide groundbreaking treatments that could potentially change the lives of patients confronting cancer.
First Quarter Highlights
The first quarter of 2025 has been marked by remarkable milestones for Zelluna ASA. A significant achievement occurred on March 3, 2025, when the company completed a strategic merger with Ultimovacs ASA and Zelluna Immunotherapy AS. This merger was coupled with a private placement that raised gross proceeds of MNOK 51.7, all while making sure the conditions for a successful integration were fulfilled.
This successful combination marks Zelluna’s strong positioning within the biotechnology sector. Following the merger, Zelluna underwent a name change and ticker code adjustment, transitioning from Ultimovacs ASA to Zelluna ASA with the ticker 'ZLNA', reflecting its new direction.
Advancements in TCR-NK Cell Therapies
Manufacturing Breakthrough
On April 22, 2025, Zelluna reported a significant leap forward in scaling and automating its proprietary manufacturing process for TCR-NK cell therapies. This advancement is not only vital for the company's clinical entry but also assures that the innovative treatments will be accessible to patients in need.
The new manufacturing process is versatile and can accommodate various products from the Zelluna pipeline, thereby enhancing efficiency and further solidifying the company's standing within the TCR-NK therapeutic domain. By allowing hundreds of doses to be produced from a single batch, this method signifies outstanding scalability and a promising reduction in costs.
Financial Overview
The financial report reveals total operating expenses amounting to MNOK 22.2 for Q1 2025. Moreover, the company faced a net negative cash flow from operational activities, registering MNOK 36.0 during the quarter. Notably, proceeds from equity issuance reached MNOK 51.7, and net cash acquired from the business combination stood at MNOK 92.3. This culminated in a net increase in cash and equivalents of MNOK 108.0 for the first quarter, bringing the total cash and cash equivalents to MNOK 135.3 by the end of March.
Additionally, a reverse share split was executed on March 31, 2025, resulting in a new outstanding share count of 20,227,066, reflecting a consolidation where ten shares became one.
Looking Ahead
As the company prepares to publish its detailed quarterly report and presentation, anticipated for May 8, 2025, stakeholders are encouraged to remain engaged. A conference call will also be held on the same day, allowing investors and interested parties to ask questions and learn more about Zelluna’s trajectory.
Investing in Zelluna ASA represents a commitment to pioneering cancer treatments that possess the potential to change patient lives. With a team rich in biotechnological experience and a clear vision for the future, Zelluna is set to make a lasting impact.
Contact Information
For more inquiries, please reach out to:
Namir Hassan, CEO, Zelluna ASA
Email: namir.hassan@zelluna.com
Phone: +44 7720 687608
Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com
Phone: +47 482 48632
About Zelluna ASA
Zelluna’s mission is to provide transformative treatments capable of curing advanced solid cancers while ensuring safety and costs are managed effectively. The company focuses on harnessing the immune system's power to develop sophisticated, “off the shelf” TCR-NK therapies that can revolutionize cancer treatment.
To learn more about Zelluna ASA and their products, please visit www.zelluna.com.
Frequently Asked Questions
What is Zelluna ASA's main focus in biotechnology?
Zelluna ASA primarily focuses on developing T Cell Receptor based Natural Killer (TCR-NK) therapies for cancer treatment, aiming for safe and effective cures.
How did Zelluna perform financially in Q1 2025?
The company reported total operating expenses of MNOK 22.2, with a cash flow increase resulting from the successful equity raise of MNOK 51.7.
What significant merger did Zelluna complete recently?
Zelluna completed a merger with Ultimovacs ASA and Zelluna Immunotherapy AS, which facilitated a transition to the new company structure.
What are the expected benefits of Zelluna's new manufacturing process?
The new manufacturing process is designed to enhance scalability, enabling the production of hundreds of doses at a lower cost, making treatments more accessible.
How can interested parties ask questions about Zelluna's performance?
Zelluna will host a conference call on May 8, 2025, allowing for direct inquiries and discussions regarding their performance and future prospects.
